ArticleBritish journal of clinical pharmacology2012
The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.
Article in British journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- PharmVar GeneFocus: SLCO1B1.Clinical pharmacology and therapeutics · 2023Review
- Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.Drug metabolism and disposition: the biological fate of chemicals · 2020Article
- Genetic contribution to lipid target achievement with statin therapy: a prospective study.The pharmacogenomics journal · 2020Observational
- Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.Clinical and translational science · 2020Observational
- Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials.Journal of personalized medicine · 2019Review
- Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia.Journal of clinical laboratory analysis · 2018Article
- Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver.Pharmacogenetics and genomics · 2013Article
- Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.Expert review of cardiovascular therapy · 2013Review
- Genomics and Precision Medicine to Direct Statin Use in the Young.Progress in pediatric cardiology · 2009Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
aimTo determine whether the SNP rs4149056 in SLCO1B1 alters the pharmacodynamics of pravastatin.
methodsrs4149056 was genotyped in 626 pravastatin-treated participants in the WOSCOPS trial and the response after 1 year of treatment was compared between the different genotypes.
resultsPravastatin reduced serum LDL cholesterol by 22.2% in TT homozygotes, by 22.2% in TC heterozygotes and by 17.7% in CC homozygotes (TT + TC vs. CC P value 0.33). There were no significant differences in the response of total cholesterol, LDL, HDL, triglycerides or CRP to pravastatin between the genotypes.
conclusionThe rs4149056 SNP did not significantly affect the pharmacodynamics of pravastatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.